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Alzheimer’s disease (AD) is characterized by the
accumulation of amyloid beta (Ab) that is assumed
to result from impaired elimination of this neurotoxic
peptide. Most patients with AD also exhibit cerebral
amyloid angiopathy, which consists of Ab deposition
within the cerebral vasculature. The contribution of
monocytes in AD has so far been limited to macro-
phage precursors. In this study, we aimed to investi-
gate whether circulating monocytes could play a role
in theeliminationofAb.With live intravital two-photon
microscopy, we demonstrate that patrolling mono-
cytes are attracted to and crawl onto the luminal walls
of Ab-positive veins, but not on Ab-positive arteries
or Ab-free blood vessels. Additionally, we report the
presence of crawling monocytes carrying Ab in veins
and their ability to circulate back into the blood-
stream. Selective removal of Ly6Clo monocytes in
APP/PS1 mice induced a significant increase of Ab
load in the cortex and hippocampus. These data un-
cover the ability of Ly6Clo monocytes to naturally
target and eliminate Ab within the lumen of veins
and constitute a potential therapeutic target in AD.
INTRODUCTION
Accumulation of amyloid beta (Ab) is a central hallmark of
Alzheimer’s disease (AD) and is assumed to result from
decreased elimination of this neurotoxic peptide (Mawuenyega
et al., 2010). Cerebral amyloid angiopathy (CAA) has emerged
as a significant contributor to this pathology (Pimentel-Coelho
and Rivest, 2012; Weller et al., 2009). CAA reflects the accumu-
lation of Ab within walls of blood vessels due to the impaired
clearance from the brain along perivascular lymphatic drainage
pathways. It has a prevalence of more than 90% in patients
with AD, correlates with cognitive deficits, and is frequently
associated with many detrimental effects such as hemorrhages
and ischemic lesions (Pimentel-Coelho and Rivest, 2012; Weller
et al., 2009). A constant equilibrium exists among parenchymal,
vascular, and peripheral Ab levels (Deane et al., 2009; Marques646 Cell Reports 5, 646–653, November 14, 2013 ª2013 The Authorset al., 2009). Consequently, lowering Ab levels in perivascular
spaces or in the circulation reduces the burden in the paren-
chyma through equilibrium-driven redistribution (Deane et al.,
2009; Hawkes and McLaurin, 2009; Sehgal et al., 2012). Thus
far, the main pathways of Ab elimination involve phagocytosis
and proteolytic degradation by mononuclear and vascular
smooth muscle cells, transcytosis across the blood-brain barrier
(BBB), and perivascular lymphatic drainage (Bell et al., 2009;
Deane et al., 2009; Weller et al., 2009). Therefore, it is now
evident that the neurovascular unit occupies a central position
and has a pivotal role for Ab clearance. The nature of the BBB
limits the access to select soluble molecules and circulating leu-
kocytes to the central nervous system (CNS) (Bellavance et al.,
2008; Ransohoff et al., 2003). Among leukocytes, monocytes
have a crucial role in AD, as monocyte-derived perivascular
macrophages are highly efficient for Ab phagocytosis (Hawkes
and McLaurin, 2009; Mildner et al., 2011). Receptor for
advanced glycation end products (RAGE), platelet endothelial
cell adhesion molecule (PECAM-1), and CXCL1 are pivotal for
Ab-induced adhesion and transendothelial migration of mono-
cytes in vitro (Giri et al., 2000; Zhang et al., 2013). Murine mono-
cytes consist of two heterogeneous subsets: patrolling
(Ly6CloCX3CR1highCCR2) and inflammatory (Ly6ChiCX3CR1int
CCR2+) monocytes. They have distinct sets of adhesion mole-
cules and chemokine receptors, which reflect their respective
functions (Geissmann et al., 2008). Following various CNS in-
sults, recruited macrophages appear to originate essentially
from inflammatory monocytes (Prinz and Priller, 2010), while
the role of patrolling monocytes is still not well defined. Recently,
patrolling monocytes were shown to originate from short-lived
inflammatory monocytes and established as terminally differen-
tiated blood-resident macrophages that act as intravascular
‘‘housekeepers’’ (Carlin et al., 2013; Yona et al., 2013). In this
study, we investigated whether patrolling monocytes could
play a role in the clearance of Ab.
RESULTS AND DISCUSSION
In order to characterize the accumulation of Abwithin the neuro-
vascular unit and examine the role of monocytes in such an
event, we performed live intravital two-photon microscopy in tri-
ple-transgenic APPswe/PS1
+//Cx3cr1gfp/+ mice (referred to
APP/PS1/Cx3cr1 from now on). We monitored the cortical
Figure 1. Age- and Vessel-Dependent Ab Deposition in APP/PS1/Cx3cr1 Mice
(A and B) Representative cortical blood vessels in an APP/PS1/Cx3cr1 mouse at 5 and 9 months, respectively. CX3CR1-expressing cells such as microglia,
perivascular macrophages, and monocytes are in green (GFP), blood vessels are in gray (Qdot 705), and Ab in red (Congo red).
(C) At 5 months old, small Ab aggregates are observed in veins (v).
(D) By 9 months of age, APP/PS1/Cx3cr1 mice developed striped rings of Ab surrounding arteries (a). Scale bars, 25 mm.
See also Figure S1 and Movie S1.microvasculature of APP/PS1/Cx3cr1mice at 5 and 9 months of
age, and two distinct patterns of Ab deposition were observed. In
younger mice (4–6 months old), small and punctate Ab aggre-
gates were deposited on specific blood vessels (Figures 1A
and 1C). With disease progression, striped rings of Ab wrapping
additional blood vessels appeared (Figures 1B and 1D) in
concomitance with the small aggregates identified at earlier
age. These two distinctive types of Ab deposition were previ-
ously reported in mice to develop in veins and arteries, respec-
tively (Dorr et al., 2012). In order to confirm the identity of these
blood vessels and the correspondence with the two patterns of
Ab deposition, we injected Alexa 633, an artery-specific dye
(Shen et al., 2012), in APP/PS1 mice. Striped rings of Ab were
located around arteries while small aggregates were exclusively
situated in veins (Figure S1). Note that divergent bifurcations or
confluent junctions also allow the differentiation between
arteries and veins. Interestingly, many of the small Ab aggregates
detected in veins were mobile, probably due to the bulk flow
(Movie S1), while striped rings surrounding arteries were mostlyCesteady. Although vascular Ab has been reported to accumulate
at higher levels around arteries, its clearance appears to occur
through a paravenous pathway (Iliff et al., 2012). Based on our
observations, small Ab aggregates on veins seem to precede
Ab deposition in arteries. Whether paravenous clearance of Ab
can become saturated or dysfunctional over time and contribute
to perivascular accumulation in arteries remains an open
question.
Because it is well established that microglia in the brain
parenchyma migrate toward Ab plaques (Simard et al., 2006),
we next investigated whether monocytes can be specifically
attracted to blood vessels containing Ab. Interestingly,
CX3CR1+ cells were found to be largely attracted to veins con-
taining small Ab aggregates and crawled onto them (Figures
2A–2H; Movie S2). Noticeably, several CX3CR1+ monocytes
could be observed crawling against the blood flow, revealing a
strong adhesion to the endothelium. Although not significant, a
slightly lower number of crawling cells were detected in 7- to
9-month-old APP/PS1/Cx3cr1 mice compared to 4- toll Reports 5, 646–653, November 14, 2013 ª2013 The Authors 647
Figure 2. Monocytes Are Selectively Attracted to Small Ab Aggregates in Veins
(A–C and E–G) Representative examples of time-lapse imaging of monocytes displacements in 5- and 9-month-old APP/PS1/Cx3cr1 mice. White dashed lines
illustrate movements of crawling monocytes over time (time in min and s).
(D) In 4- to 6-month-oldmice, crawlingmonocytes are significantly more frequent in veins (v) containing small Ab aggregates compared to Ab-free vessels of APP/
PS1/Cx3cr1 and WT mice.
(H) In 7- to 9-month-old mice, crawling monocytes were not observed in arteries (a) containing Ab striped rings, while they were still significantly more frequent in
veins containing small Ab aggregates.
(I–K) Crawling monocytes were rarely observed in blood vessels of WT mice. Data are expressed as mean ± SEM; a total of five APP/PS1/Cx3cr1 and two WT
mice were analyzed; n = 30 and n = 27 blood vessels for mice 4–6 and 7–9 months old; *p < 0.05, **p < 0.01, ***p < 0.001 (versus Ab+ veins). Scale bar, 25 mm.
See also Movies S2, S3, and S4.6-month-old mice. Essentially, no monocyte was crawling onto
arteries with striped rings of Ab (Figures 2E–2H; Movie S3). In
Cx3cr1gfp/+ mice, we noted very rare rolling or crawling mono-
cytes during all the imaging sessions performed and at any
age (Figures 2I–2K; Movie S4). Thus, our findings reveal that
there are frequent and close interactions between monocytes
and veins harboring Ab aggregates. Indeed, even if Ab buildup
triggers a systemic inflammatory response, monocytes seem
selectively attracted to these vessels and not to their adjacent
Ab-free counterparts or Ab+ arteries. It is likely that Ab deposits
within the walls of veins directly or indirectly activate endothelial
cells. Specific features of the endothelium of these vessels must
also promote this preferential adhesion, in accordance with our648 Cell Reports 5, 646–653, November 14, 2013 ª2013 The Authorsdata as well as with numerous lines of evidence reporting that
leukocytes normally adhere to veins rather than to arteries prior
to infiltrating the inflamed CNS (Bechmann et al., 2007; Ransoh-
off et al., 2003).
Heretofore, the in vivo ability of monocytes to phagocytose
endogenously produced Ab was mostly speculative. In APP/
PS1/Cx3cr1 mice, we observed several crawling monocytes
that were carrying Congo red+ clusters, suggesting the presence
of intracellular Ab aggregates (Figures 3A–3O; Movies S1, S5,
and S6). Thesemonocytes were found exclusively in veins exhib-
iting small Ab aggregates. While perceivable Congo red aggre-
gates imply the presence of fibrillar aggregates formed of b
sheets of Ab, it does not rule out the uptake and degradation
Figure 3. Crawling Monocytes Can Internalize Ab and Circulate Back to the Bloodstream
(A–O) Time-lapse imaging of three different crawling monocytes carrying congophilic Ab aggregates in 5.5-month-old APP/PS1/Cx3cr1 mice.
(K–O) A monocyte containing two visible clusters of Ab is crawling toward a larger caliber vein to eventually lose its adherence and leave into the bloodstream.
Scale bar, 10 mm.
See also Movies S1, S5, and S6.of small noncongophilic Ab by monocytes. In this regard, macro-
phages continuously exposed to Abmonomers are able to accu-
mulate intracellular Ab over time, leading to the formation of
aggregates that can be further stained with Congo red (Cui
et al., 2002). Therefore, b sheets of Ab observed in monocytes
could result from the buildup of small Ab monomers/oligomers
internalized in lysosomes or the direct phagocytosis of fibrillar
Ab aggregates. This would imply the presence of intraluminal
Ab aggregates and/or the direct uptake of Ab across the endo-
thelium. It is also well established that once inside the perivascu-
lar space of veins, Ab can reach the bloodstream across the
endothelium by receptor-mediated transcytosis (Deane et al.,
2009; Iliff et al., 2012). Whether internalized Ab aggregates are
degraded remains uncertain but many evidence support the
capacity of monocytes/macrophages to eliminate Ab with
much greater efficiency than microglia (Fiala et al., 2007; Liu
et al., 2010; Majumdar et al., 2008; 2007; Simard et al., 2006).
Of particular interest, Ab+ monocytes eventually lose their adhe-
sion to the endothelium and leave towards the bloodstream
(Figures 3K–3O; Movie S1), which suggests a novel mechanism
underlying the beneficial role of these circulating cells in AD.
Because systemic Ab degradation is extremely efficient (Deane
et al., 2009; Hawkes and McLaurin, 2009; Sehgal et al., 2012),Ceconveying Ab in the bloodstream typically increases its efflux
speed from the brain, presumably by an equilibrium-driven redis-
tribution process.
In striking contrast to older APP/PS1/Cx3cr1mice where peri-
vascular Ab deposition was generally stable, we observed very
dynamic kinetics of Ab accumulation and clearance in veins of
young APP/PS1/Cx3cr1mice. Serial imaging sessions were initi-
ated in a 4.5-month-old APP/PS1/Cx3cr1 mouse in a field in
which two perpendicular blood vessels (horizontal artery and
vertical vein) were free of Ab and basically no GFP+ monocytes
were crawling onto their luminal surfaces (Figures 4A–4C; Movie
S7). Imaging the same two vessels 7 and 21 days later revealed
the appearance of many Ab aggregates on the vertical vein (Fig-
ures 4D–4I; Movies S8 and S9). Importantly, this was accompa-
nied by the crawling of few monocytes on this vessel, while no
monocyte adhered to the horizontal Ab-free artery. Remarkably,
28 days following the first imaging session, Ab aggregates
mostly disappeared and, correspondingly, crawling monocytes
were no longer seen in this vertical vessel (Figures 4J–4L; Movie
S10). As a positive control in the same mouse, a crawling
monocyte containing Ab aggregates was imaged in an adjacent
Ab+ vein (Figures 3A–3E; Movie S5). These results demonstrate
that, at least in young APP/PS1 mice, the deposition ofll Reports 5, 646–653, November 14, 2013 ª2013 The Authors 649
Figure 4. Dynamic Deposition of Ab and
Corresponding Monocyte Crawling
Successive time-lapse images in a 4.5-month-old
APP/PS1/Cx3cr1 mouse. A vertical vein (v) and a
horizontal artery (a) both free of Ab were acquired
with a two-photon microscope over time (days 1,
7, 21, and 28).
(A–C) At day 1, no GFP+ monocytes were crawling
on either blood vessel.
(D–I) Seven and 21 days later, small Ab aggregates
appeared on the vertical vein and crawling
monocytes were recruited in this specific vessel.
(J–L) Finally, 28 days after the first imaging
session, almost no aggregates and no crawling
monocytes were detected. In all the imaging
sessions, no Ab or crawling monocytes were seen
in the horizontal artery. Scale bar, 10 mm.
See also Movies S7, S8, S9, and S10.small Ab aggregates in veins can be dynamic and thus underlies
its potential to be cleared by circulating monocytes. Further-
more, these events support the fact that monocyte crawling cor-
relates with the presence of Ab aggregates on these blood
vessels.
Several characteristics of patrolling Ly6Clo monocytes in the
periphery (Carlin et al., 2013) ledus tohypothesize that thesecells
correspond to the crawling monocytes observed in our study.
Indeed, Ly6Clo monocytes monitor and crawl inside the lumen
of blood vessels independently of the blood flow. They display
several filopodia-like protrusions in contact with the endothelium
as well as large endosomes containing endogenous microparti-
cles. As observedwith internalized Ab (Figure 3), uptake ofmicro-
particles is not necessarily followed by instant detachment from
the endothelium because patrolling monocytes can carry their
cargo for more than 25 min. Interestingly, patrolling monocytes
were also found to orchestrate the disposal of endothelial cells
and scavenge cellular debris within the lumen (Carlin et al., 2013).650 Cell Reports 5, 646–653, November 14, 2013 ª2013 The AuthorsTo validate our hypothesis, we selec-
tively deprived the mice of Ly6Clo patrol-
ling monocytes. The differentiation and
survival of these monocytes are depen-
dent on the Nr4a1 (Nur77) transcription
factor (Hanna et al., 2011). Indeed, mice
lacking Nr4a1 in bone marrow (BM) cells
have an important reduction in the num-
ber of Ly6Clo monocytes and the few
remaining cells are undifferentiated and
dysfunctional. Nonetheless, the other
blood leukocytes remain unaffected. We
thus transplanted myeloablated APP/
PS1 mice with Nr4a1/Gfp+/
(Nr4a1/Gfp+/ / APP/PS1) or Gfp+/
(Gfp+/ / APP/PS1) BM cells. Both
groups of chimeric mice had similar blood
chimerism and proportion of total blood
monocytes (Figure 5A). As expected,
GFP+ cells in Nr4a1/Gfp+/ / APP/
PS1 chimeric mice had very low levelsof Ly6Clo monocytes. The number of crawling GFP+ cells in
Ab+ veins of Gfp+// APP/PS1 chimeras was similar to APP/
PS1/Cx3cr1mice (Figure 5B). In contrast, an important reduction
of the amount of crawlingmonocytes wasmonitored in Ab+ veins
ofNr4a1/Gfp+// APP/PS1 mice. BecauseNr4a1 deficiency
affects only Ly6Clo monocytes, this result indicates that they
represent the vast majority of the crawling monocytes observed.
Note that no crawling monocyte was observed in Ab+ arteries
throughout all imaging sessions (data not shown).
To evaluate the impact of these patrolling monocytes
throughout disease progression, we transplanted wild-type
(WT) or Nr4a1/ BM cells in 2.5-month-old myeloablated
APP/PS1 mice and performed histologic analysis 5 months
later. Myeloablation was induced with busulfan/cyclophospha-
mide because it provides an excellent level of chimerism
but does not entail the artificial recruitment of circulating
cells to the brain parenchyma (Lampron et al., 2012).
Accordingly, in 7.5-month-old APP/PS1 mice that have been
Figure 5. Depletion of Ly6Clo Monocytes Reduces Cell Crawling Inside Ab+ Veins and Increases Ab Deposition
6- to 7-month-old myeloablated APP/PS1 mice were transplanted with whole bone marrow cells from Gfp+/ or Nr4a1/Gfp+/ mice.
(legend continued on next page)
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transplanted with Cx3cr1gfp/+ BM cells and have a near-perfect
blood chimerism (data not shown), we observed essentially no
GFP+ cells in the parenchyma and only very rare GFP+ cells
that were associated with blood vessels (Figure 5C, left andmid-
dle panel). As a positive control, many GFP+ ramified paren-
chymal microglia are present in nonchimeric APP/PS1/Cx3cr1
mice (Figure 5C, right panel). Blood leukocytes analysis of
Nr4a1// APP/PS1 chimeric mice revealed a selective reduc-
tion of Ly6Clomonocytes, while the total concentrations ofmono-
cytes, granulocytes, and T cells were not statistically different
from WT / APP/PS1 control mice (Figure 5D). Post mortem
analysis of these mice revealed that both the number and the
area covered by Ab deposits in 7.5-month-old Nr4a1/ /
APP/PS1 chimeric mice were significantly higher in the cortex
and hippocampus compared to WT/ APP/PS1 (Figure 5E).
Together, these data provide evidence that Ly6Clo patrolling
monocytes are located at a key position, contacting frequently
and selectively Ab-laden veins and scavenging Ab from the
lumen. Over the course of the disease, such natural interactions
could be less effective and contribute to the marked vascular Ab
deposition. Of particular interest, plasma levels of macrophage
colony-stimulating factor, recently shown to be critical for the
survival of Ly6Clo monocytes (Yona et al., 2013), are lower in
AD patients (Ray et al., 2007). Accordingly, this could underlie
the beneficial effects of chronic administration of this hemato-
poietic cytokine in APP/PS1 mice (Boissonneault et al., 2009).
Almost a decade ago, Fiala et al. reported that monocytes iso-
lated from AD patients and exposed to Ab exhibited low phago-
cytosis, abnormal cytokines release, and increased apoptosis
(Fiala et al., 2005). Therefore, stimulating the production of new
and functional bloodmonocytes could counteract these defects.
Because an equilibrium exists among parenchymal, vascular,
and peripheral Ab levels (Deane et al., 2009; Marques et al.,
2009), increasing vascular Ab clearance by patrolling monocytes
could have significant impact on AD. In this regard, reducing
the migration, phagocytosis, or number of mononuclear cells in
transgenic AD mice is detrimental, whereas compounds
increasing their number and phagocytic activity are generally
beneficial (Michaud et al., 2013; Rivest, 2009). So far, circulating
monocytes were regarded as mere macrophage precursors in
AD. We propose herein a paradigm for the elimination of Ab
from the CNS that is assumed by patrolling monocytes. Whether
this mechanism of Ab removal leads to cognitive improvements
remains to be determined, but if so, this will represent an attrac-
tive therapeutic target for AD.(A) Flow cytometry analysis of blood chimerism (% of GFP+ cells in total CD45+ le
the CD45+GFP+ cell population and identified as CD11b+CD115+Ly6G. The
Nr4a1/Gfp+// APP/PS1 compared toGfp+// APP/PS1 chimeric mice. Cra
were initiated 1 month later.
(B) Number of crawling monocytes onto Ab+ veins in Gfp+// APP/PS1 (n = 4; n
vessels). For histological analysis, APP/PS1 mice underwent a myelosuppressive
cells from Cx3cr1gfp/+, WT, or Nr4a1/ mice.
(C) Virtually no GFP+ cells were detected in the parenchyma ofCx3cr1gfp/+/APP
few cells (white arrowhead) observed were usually associated with blood vessel
across the brain parenchyma of nonchimeric APP/PS1/Cx3cr1 mice (right panel)
(D) Flowcytometryquantificationofblood leukocytesof 7.5-month-oldAPP/PS1mi
(E) Unbiased stereological analysis of the number and area of fibrillar Ab (Congo r
WT/ APP/PS1 mice (n = 8 per group; scale bar, 500 mm). Data are expressed
652 Cell Reports 5, 646–653, November 14, 2013 ª2013 The AuthorsEXPERIMENTAL PROCEDURES
All mice were maintained in a pure C57BL/6J background. Animal procedures
were conducted according to the Canadian Council on Animal Care guide-
lines, as administered by the Laval University Animal Welfare Committee.
Cranial window was installed after part of the scalp was removed and the right
parietal bone was gently thinned. A 5mm round glass coverslip was laid on the
dura mater and fixed with cyanoacrylate glue. Mice were allowed to recover
during at least 3 weeks before intravital imaging experiments were initiated.
Prior to the imaging sessions (at least 48 hr), Ab was stained with Congo red
injected in the cerebral spinal fluid via the cisterna magna. Immediately before
imaging, Qdot 705 was injected via the tail vein to label blood vessels. Intravital
imaging was carried with an Olympus FV1000 multiple-photon excitation
(MPE) two-photon microscope equipped with a Mai Tai DeepSee laser tuned
at 890 or 905 nm and an Olympus Ultra 253 MPE water immersion objective
(1.05 NA). Images were acquired at a zoom factor ranging from 1.03 to 5.03
and blood vessels were used as landmarks for chronic intravital imaging. Flow
cytometry analysis of whole blood was performed as described previously
(Michaud et al., 2013). Briefly, blood was incubated on ice 20 min with
CD16/CD32 and further stained for 40 min with the following anti-mouse anti-
bodies at their predetermined optimal concentration: CD45-V500, CD11b-
A700, CD115-APC, Ly6G-PE, Ly6C-V450, and CD3e-PE-Cy7. Red blood cells
were lysed and leukocytes were acquired on a flow cytometer (BD LSR II). For
two-photon microscopy of chimeric mice, 6- to 7-month-old APP/PS1 mice
were exposed to 5 Gy total-body irradiation (cobalt-60) and transplanted
with 1 3 107 freshly collected and purified BM cells from Gfp+/ or
Gfp+/Nr4a1/ mice. Cranial window installation and intravital imaging were
performed at 7–8 and 8–9 months, respectively. Chimeric APP/PS1 mice
used for histological analysis were myeloablated with 80 mg/kg of busulfan
and 200 mg/kg of cyclophosphamide and transplanted with 1 3 107 freshly
collected and purified BM cells from WT or Nr4a1/ mice. To stain Ab
plaques, free-floating sections were immunolabeled with the monoclonal
anti-Ab (6E10) or with Congo red. Blood vessels were labeled with a mono-
clonal antibody against CD31. The number of plaques and the area occupied
by all Ab-labeled plaques were determined by stereological analysis as
described previously (Simard et al., 2006).
A detailed description of all methods is provided in the Supplemental
Information.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
one figure, and ten movies and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2013.10.010.
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